Gain Therapeutics Reports 12-Month Data, Plans Phase 2 for Q1 2027
Gain Therapeutics announced 12-month open-label rexaceract data showing stable MDS-UPDRS motor scores and plans to initiate a Phase 2 trial in Q1 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.